Application for COVID-19 vaccine Nuvaxovid against Omicron variant XBB.1.5 withdrawn

The manufacturer Novavax is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland


Future Health Pharma GmbH has announced on behalf of the manufacturer Novavax that it will not be pursuing the change of marketing authorisation for its COVID-19 vaccine adapted against Omicron sub-variant XBB.1.5. The pharmaceutical company has withdrawn the application for authorisation of the protein-based vaccine Nuvaxovid submitted to Swissmedic on 30 August 2023.

No new applications for authorisation of COVID-19 vaccines against the XBB.1.5 variant are therefore currently pending in Switzerland. The Comirnaty XBB.1.5 vaccine from Pfizer and the Spikevax XBB.1.5 vaccine from Moderna Switzerland GmbH have already been approved.

Supplementary information

Media Unit

+41 58 462 02 76